Niraparib tablets

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML): MDS/AML occurs in patients exposed to LuciNira and some cases are fatal. Monitor the patient for hematologic toxicity and discontinue treatment if diagnosed with MDS/AML.
• Myelosuppression: complete blood counts are measured weekly in the first month, monthly in the next 11 months, and clinically significant changes are periodically detected thereafter.
• Blood Pressure and Cardiovascular Effects: Monitor blood pressure and heart rate at least weekly for the first 2 months, monthly for the first year, and periodically thereafter during LuciNira treatment. If necessary, administer with anti-Blood Pressure drugs and adjust the dose of LuciNira.
• Posterior reversible encephalopathy syndrome (Pres): patients treated with LuciNira developed Pres. If you confirm Pres, stop LuciNira.
• Embryo-fetal toxicity: LuciNira can cause harm to the fetus. Women of childbearing potential are advised to be aware of potential risks to the fetus and to use effective contraception.

Medication risks

Adverse Reactions
The most common adverse reactions (incidence ≥ 10%) in patients treated with LuciNira are nausea, thrombocytopenia, anemia, fatigue, constipation, musculoskeletal pain, abdominal pain, vomiting, neutropenia, decreased appetite, leukopenia, insomnia, headache, dyspnea, rash, diarrhea, Blood Pressure, cough, dizziness, acute kidney injury, urinary tract infection, and hypomagnesemia.